ClinicalTrials.gg
Active, not recruitingNCT05113251Updated Aug 11, 2026Results posted

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

A Phase 3 interventional study of Trastuzumab Deruxtecan and Paclitaxel in Breast Neoplasms, Breast Cancer and HER2-positive Early Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 145 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
927
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
3rd of 58
927 · median 139
Started
2021
with 2 others
Phase 3
12 of 58
3 open now
Primary completion
2025-03
later than 5 of 44 live
Registered
21st of 58
by date
Lead sponsor
9 of 58
AstraZeneca

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 5 of the 44 other live ones, and was the 21st registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

Read the detailed description

The target population of interest in this study is participants with high-risk HER2-positive early-stage breast cancer. The purpose of this study is to determine the efficacy and safety of T-DXd neoadjuvant therapy.

Participants will be randomised to one of 3 arms: T-DXd monotherapy (Arm A), T-DXd followed by THP (Arm B), or ddAC-THP (Arm C).

03

Conditions studied

  • Breast Neoplasms
  • Breast Cancer
  • HER2-positive Early Breast Cancer

Browse trials for

Keywords

  • Trastuzumab Trastuzumab Deruxtecan (T-DXd; DS-8201a)
  • DESTINY-BREAST11
  • Receptor, ErbB-2
  • breast neoplasms
  • Antineoplastic Agents, Phytogenic
  • Antineoplastic Agents;Molecular Mechanisms of Pharmacological Action
  • DB11
  • Enhertu
  • HER2 (human epidermal growth factor receptor 2)
  • breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must be at least 18 years of age.
  • documented -positive early breast cancer (EBC) participants, including clinical stage at presentation (based on mammogram or breast MRI assessment): T0-4 (inclusive of inflammatory breast cancer), N1-3, M0 or ≥ T3, N0, M0 as determined by the AJCC staging system, 8th edition
  • performance status of 0 or 1 at randomization
  • Adequate organ and bone marrow function
  • ≥ 50% within 28 days before randomization
  • FFPE tissue block (2 cores) or 20 freshly-cut, serial tumor slides for HER2 assessment by central lab. If blocks are incomplete or fewer than 20 slides are available, participants may be eligible following discussion with the AstraZeneca Study Physician

Exclusion Criteria:

  • prior history of invasive breast cancer
  • stage IV breast cancer (determined by AJCC staging system)
  • any primary within 3 years (except resected non-melanoma skin cancer, curatively treated in situ disease) Note: This includes a second current breast primary malignancy (ie, bilateral breast cancer)
  • history of DCIS (except those treated with mastectomy >5 years prior to current diagnosis)
  • History of, or current, ILD/pneumonitis
  • Prior systemic therapy for the treatment of breast cancer
  • Previous treatment with anthracyclines, cyclophosphamide or taxanes for any malignancy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
927 participants (actual)

Study arms

  • Experimental
    Arm A

    Trastuzumab deruxtecan

    Drug: Trastuzumab Deruxtecan

  • Experimental
    Arm B

    T-DXd, followed by THP

    Drug: Trastuzumab Deruxtecan · Drug: Paclitaxel · Drug: Trastuzumab · Drug: Pertuzumab

  • Active comparator
    Arm C

    doxorubicin and cyclophosphamide, followed by THP

    Drug: Paclitaxel · Drug: Trastuzumab · Drug: Pertuzumab · Drug: Doxorubicin · Drug: cyclophosphamide

Interventions

  • administered by intravenous infusion

    Also known as: T-DXd, Enhertu

  • administered by intravenous infusion

    Also known as: Taxol, Onxol

  • administered by intravenous infusion

    Also known as: Herceptin, Herzuma

  • administered by intravenous infusion

    Also known as: Perjeta

  • administered by intravenous infusion

    Also known as: Adriamycin, Rubex

  • administered by intravenous infusion

    Also known as: Neosar, Cytoxan

06

What researchers measure

Primary outcomes

  1. Rate of Pathologic Complete Response (pCR).

    Proportion of participants who have no evidence by Hematoxylin \& Eosin (H\&E) staining of residual invasive disease in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by central evaluation following completion of neoadjuvant therapy.

    Time frame: Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)

Secondary outcomes

  1. Event-Free Survival (Count)

    Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.

    Time frame: Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)

  2. Event-Free Survival (Duration)

    Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.

    Time frame: Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)

07

Results

Posted Jun 9, 2026
Limitations and caveats
On 13 March 2024, enrolment to the T-DXd-alone arm was prematurely closed following the recommendation of the Independent Data Monitoring Committee (IDMC). Patients already receiving T-DXd alone could continue treatment until completion of eight cycles, meeting any discontinuation criteria, or switching to the investigator's choice of local SOC-classified as having a non-pCR.

Participant flow

The study is active, not recruiting and conducted in 18 countries worldwide across 147 centres, with 927 patients who were randomized up until 24th April 2024. Results are reported for the study at the data cut-off for the primary analysis for pathologic complete response (pCR) on 12th March 2025.

Participant flow — Overall Study
MilestoneArm AArm BArm C
Started286321320
Completed000
Not completed286321320
Withdrew: Death839
Withdrew: Withdrawal by subject11421
Withdrew: As recorded on the case report form (crf).112
Withdrew: Ongoing at the time of primary analysis for pcr266313288

Outcome measures

PrimaryRate of Pathologic Complete Response (pCR).

Proportion of participants who have no evidence by Hematoxylin \& Eosin (H\&E) staining of residual invasive disease in the complete resected breast specimen and all sampled regional lymph nodes (ypT0/Tis ypN0) by central evaluation following completion of neoadjuvant therapy.

Time frame:
Through to definitive surgery or discontinuation/withdrawal from study, up to a maximum of approximately 40 months from randomization to primary pCR DCO (12MAR2025)
Reported as:
Number · Percentage of participants
Rate of Pathologic Complete Response (pCR).
Percentage of participantsArm AArm BArm C
Rate of Pathologic Complete Response (pCR).43.0167.2956.25
Statistical analysis
  • Arm A vs Arm C · Miettinen and Nurminen's (M&N) method · p = 0.001 · M&n estimate of difference in rates: -13.18 · 95% CI -20.84 to -5.41A difference in rates \> 0 favours T-DXd to be associated with a higher rate of pCR than ddAC-THP.
  • Arm B vs Arm C · Miettinen and Nurminen's (M&N) method · p = 0.003 · M&n estimate of difference in rates: 11.17 · 95% CI 3.95 to 18.28A difference in rates \> 0 favours T-DXd-THP to be associated with a higher rate of pCR than ddAC-THP.
SecondaryEvent-Free Survival (Count)

Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.

Time frame:
Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)

Results for this outcome have not been posted.

SecondaryEvent-Free Survival (Duration)

Event-free survival (EFS) is defined as the time from date of randomization until disease progression precluding initial surgery, invasive disease recurrence (local, regional, distant, or contralateral), or death from any cause.

Time frame:
Up to a maximum of approximately 65 months from randomization to EFS final analysis DCO (Apr 2027)

Results for this outcome have not been posted.

Adverse events

Collected over All-cause mortality: from date of randomization through to death due to any cause. Adverse events and SAEs are reported from the first dose date, throughout the treatment period and the safety follow-up period (until 40 + 7 days after the discontinuation of all study interventions). Both up to a maximum of approximately 40 months to primary pCR DCO (12MAR2025).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
T-DXd8/286 (2.8%)29/283 (10.2%)269/283 (95.1%)
T-DXd-THP3/321 (0.9%)34/320 (10.6%)306/320 (95.6%)
ddAC-THP9/320 (2.8%)63/312 (20.2%)307/312 (98.4%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventT-DXdT-DXd-THPddAC-THP
PneumoniaInfections and infestations3/2831/3209/312
PneumonitisRespiratory, thoracic and mediastinal disorders1/2834/3207/312
Febrile neutropeniaBlood and lymphatic system disorders0/2831/3207/312
AnaemiaBlood and lymphatic system disorders1/2830/3205/312
MyelosuppressionBlood and lymphatic system disorders0/2830/3205/312
NeutropeniaBlood and lymphatic system disorders0/2830/3205/312
PyrexiaGeneral disorders0/2832/3204/312
Covid-19Infections and infestations3/2833/3203/312
Alanine aminotransferase increasedInvestigations0/2832/3203/312
Aspartate aminotransferase increasedInvestigations0/2830/3203/312
Most frequent other events
Showing 10 of 56
Most frequent other events
EventT-DXdT-DXd-THPddAC-THP
NauseaGastrointestinal disorders193/283207/320161/312
DiarrhoeaGastrointestinal disorders64/283187/320168/312
AlopeciaSkin and subcutaneous tissue disorders120/283152/320153/312
AnaemiaBlood and lymphatic system disorders42/28373/320152/312
ConstipationGastrointestinal disorders95/28393/32076/312
VomitingGastrointestinal disorders87/28391/32066/312
StomatitisGastrointestinal disorders39/28359/32086/312
FatigueGeneral disorders66/28374/32082/312
Neuropathy peripheralNervous system disorders11/28383/32065/312
Alanine aminotransferase increasedInvestigations63/28377/32080/312

Baseline characteristics

This population includes all randomized patients.

Age, Categorical
Age, Categorical(Participants)Arm AArm BArm CTotal
<=18 years0000
Between 18 and 65 years252282288822
>=65 years343932105
Age, Continuous
Age, Continuous(Years)Arm AArm BArm CTotal
Mean50.3 ± 11.2550.0 ± 11.0950.1 ± 11.3250.1 ± 11.21
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BArm CTotal
Female286321320927
Male0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BArm CTotal
Hispanic or Latino28292885
Not Hispanic or Latino257292292841
Unknown or Not Reported1001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm AArm BArm CTotal
Black or African American75719
Native Hawaiian or other Pacific Islander0112
American Indian or Alaska Native2204
Asian127160157444
White139140137416
Other69924
Not reported54918
Height
Height(cm)Arm AArm BArm CTotal
Mean160.248 ± 7.0934159.793 ± 6.8713160.441 ± 7.1728160.158 ± 7.0434
Weight
Weight(kg)Arm AArm BArm CTotal
Mean66.212 ± 15.246564.879 ± 12.380766.284 ± 14.586765.776 ± 14.0814
BMI
BMI(kg/m2)Arm AArm BArm CTotal
Mean25.717 ± 5.310025.383 ± 4.614325.724 ± 5.213025.604 ± 5.0432

2 further baseline measures are reported on the registry.

08

Study locations

145 sites
  • Research Site
    Springdale, Arkansas 72762, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    New Haven, Connecticut 06510, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    Louisville, Kentucky 40202, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    Las Vegas, Nevada 89102, United States
  • Research Site
    East Brunswick, New Jersey 08816, United States
  • Research Site
    Summit, New Jersey 07901, United States
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Ogden, Utah 84405, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Goiânia, 74000-000, Brazil
  • Research Site
    Ijuí, 98700-000, Brazil
  • Research Site
    Natal, 59075-740, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Porto Alegre, 91350-200, Brazil
  • Research Site
    São Paulo, 01221-020, Brazil
  • Research Site
    São Paulo, 01229-010, Brazil
  • Research Site
    Panagyurishte, 4500, Bulgaria
  • Research Site
    Sofia, 1330, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 1Z2, Canada
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Montreal, Quebec H4A-3J1, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Montreal, H3T 1E2, Canada
  • Research Site
    Beijing, 100039, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Chongqing, 400030, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510700, China
  • Research Site
    Kunming, 650118, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Qingdao, 266100, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenyang, 110001, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Wuhan, 430079, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Augsburg, 86156, Germany
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Erlangen, 91054, Germany
  • Research Site
    Hamburg, 20357, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Kiel, 24105, Germany
  • Research Site
    Leipzig, 4103, Germany
  • Research Site
    Mönchengladbach, 41061, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Paderborn, 33098, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Gurgaon, 122001, India
  • Research Site
    Howrah, 711103, India
  • Research Site
    Nagpur, 440001, India
  • Research Site
    Nashik, 422002, India
  • Research Site
    New Delhi, 110 085, India
  • Research Site
    New Delhi, 110029, India
  • Research Site
    Raipur, 492001, India
  • Research Site
    Rishikesh, 249203, India
  • Research Site
    Surat, 395002, India
  • Research Site
    Thiruvananthapuram, 695011, India
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Candiolo, 10060, Italy
  • Research Site
    Livorno, 57100, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Negrar, 37024, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Chūōku, 104-8560, Japan
  • Research Site
    Chūōku, 862-8655, Japan
  • Research Site
    Hidaka-shi, 350-1298, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Kawasaki-shi, 216-8511, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Nagoya, 466-8560, Japan
  • Research Site
    Nagoya, 467-8602, Japan
  • Research Site
    Ota-shi, 373-8550, Japan
  • Research Site
    Shinjuku-ku, 162-8655, Japan
  • Research Site
    Lima, 15033, Peru
  • Research Site
    Lima, LIMA 29, Peru
  • Research Site
    Lima, Lima 32, Peru
  • Research Site
    Lima, LIMA 34, Peru
  • Research Site
    Bacolod, 6100, Philippines
  • Research Site
    Cebu City, 6000, Philippines

Showing the first 100 of 145 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient data from AstraZeneca Group of Companies, sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ Disclosure Commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved, AstraZeneca will provide access to the de-identified patient level data in an approved sponsor tool. Signed Data Sharing Agreements (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Mar 2025, 40 months.

Results were first posted in Jun 2026, 1 year 2 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 40 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2021
First posted
Nov 9, 2021
StartActual
Oct 25, 2021
Primary completionActual
Mar 12, 2025
CompletionEst.
Apr 30, 2027
Results first posted
Jun 9, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05113251
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Oct 25, 2021
Primary completion
Mar 12, 2025
Completion
Apr 30, 2027 (estimated)
Results posted
Jun 9, 2026
Last update
Aug 11, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Trastuzumab deruxtecan · Trastuzumab

Start the discussion